Tetraphase Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$144.8M
Lead Investor(s):Piper Jaffray, BMO Capital Markets

Estimated Revenue & Financials

  • Tetraphase Pharmaceuticals's estimated annual revenue is currently $1.9M per year.(?)
  • Tetraphase Pharmaceuticals received $6.9M in venture funding in July 2017.
  • Tetraphase Pharmaceuticals's estimated revenue per employee is $12,685
  • Tetraphase Pharmaceuticals's total funding is $144.8M.

Employee Data

  • Tetraphase Pharmaceuticals has 149 Employees.(?)
  • Tetraphase Pharmaceuticals grew their employee count by 34% last year.
  • Tetraphase Pharmaceuticals currently has 3 job openings.

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase's proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol TTPH. Tetraphase is well positioned to be a major player in the multidrug-resistant arena.

keywords:Biotechnology, Healthcare